|Year : 2017 | Volume
| Issue : 2 | Page : 159-161
PSMA expression in multinodular thyroid neoplasm on simultaneous Ga-68-PSMA PET/MRI
Amarnath Jena1, Shuaib Zaidi2, Vikas Kashyap3, Abhishek Jha1, Sangeeta Taneja1
1 Department of Molecular Imaging and Nuclear Medicine, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi, India
2 Department of Surgical Oncology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi, India
3 Department of Pathology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi, India
|Date of Web Publication||16-Mar-2017|
Dr Amarnath Jena
Senior Consultant, Department of Molecular Imaging and Nuclear Medicine, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi
Source of Support: None, Conflict of Interest: None
| Abstract|| |
PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI.
The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted USG-guided FNAC which revealed Hurthle cell neoplasm. Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.
Keywords: Hurthle cell adenoma, PET/MRI, PSMA, prostate carcinoma, thyroid carcinoma
|How to cite this article:|
Jena A, Zaidi S, Kashyap V, Jha A, Taneja S. PSMA expression in multinodular thyroid neoplasm on simultaneous Ga-68-PSMA PET/MRI. Indian J Nucl Med 2017;32:159-61
|How to cite this URL:|
Jena A, Zaidi S, Kashyap V, Jha A, Taneja S. PSMA expression in multinodular thyroid neoplasm on simultaneous Ga-68-PSMA PET/MRI. Indian J Nucl Med [serial online] 2017 [cited 2022 Jan 22];32:159-61. Available from: https://www.ijnm.in/text.asp?2017/32/2/159/202248
| Case report|| |
A 66-year-old male with the history of prostate carcinoma, who underwent transurethral resection of the prostate 2 years back with raised PSA level and suspected spinal metastases, was referred for Ga-68-PSMA whole-body simultaneous PET/MRI scan for restaging. A bulky T2W hypointense mass was noted in residual prostate involving right seminal vesicle [Figure 1]a with the base of the bladder and mesorectal fascia, showing diffusion restriction [Figure 1]b and [Figure 1]c, increased Ktrans [Figure 1]d and increased PSMA uptake SUV max = 12.1 to 21.1 [Figure 1]e and [Figure 1]f. No enlarged/PSMA avid nodes were seen. Widespread PSMA avid marrow lesions were seen extensively involving the spine [Figure 1]g and [Figure 1]h and the remaining skeleton with SUV max = 8.5 to 27.5 [Figure 1]i.
|Figure 1: Representative PET/MRI images of a bulky hypointense mass (a) axial T2 is noted in residual prostate showing diffusion restriction (b) DWI with b = 800 and (c) ADC, (d) increased Ktrans and (e) increased PSMA uptake (f) fused PET/MRI. No enlarged/PSMA avid nodes were seen. Sagittal STIR (g) and fused PET/MRI (h) images showing PSMA avid marrow lesions. MIP PET (i) image showing wide spread PSMA avid metastases in the remaining skeleton.|
Click here to view
Further, an enlarged thyroid gland showing multiple nodules of varying intensity and sizes involving both lobes [Figure 2]a-[Figure 2]c was observed with focal increased PSMA uptake [Figure 2]d-[Figure 2]f on the left side with SUV max = 5.9. No enlarged/ PSMA avid nodes were seen in bilateral neck.
|Figure 2: Representative PET/MRI image of an enlarged thyroid gland showing multiple nodules (a-c) axial T1; T2 and sagittal STIR respectively and focal areas of PSMA uptake (d-f) axial PET; axial fused PET/MRI and sagittal fused PET/MRI respectively.|
Click here to view
USG-guided FNAC of thyroid was done which was reported as Hurthle cell neoplasm. Subsequently, total thyroidectomy was performed and the excised gland was sent for HPE which revealed multiple large nodules in both lobes consistent with Hurthle cell adenoma [Figure 3]a. In addition, small sub centimeter foci showing tubule-papillary architecture of papillary carcinoma [Figure 3]b were also noted in both lobes of thyroid. Subsequently, immunohistochemistry analysis was carried out and the thyroid lesions were found to show intense expression for thyroglobulin [Figure 3]c and no expression for PSA [Figure 3]d thereby ruling out metastases from PCa and proving that it is a primary thyroid neoplasm. A small pretracheal node sampled during surgery was reported to have metastases from papillary thyroid carcinoma based on its follicular architecture [Figure 3]e and [Figure 3]f. The pretracheal node was positive for thyroglobulin and negative for PSA [Figure 3]g and [Figure 3]h. Central compartment neck lymph nodes showed no evidence of metastases. There was no lymphovascular, perineural, capsular invasion and extension into the perithyroidal soft tissue associated with any of the tumors.
|Figure 3: Histopathological examination showed (a) multiple large nodules in both lobes consistent with Hurthle cell adenoma, 10X, comprising of microfollicles lined by cuboidal cells showing abundant deeply eosinophilic cytoplasm. (b) Sub centimeter foci showing tubule-papillary architecture of papillary carcinoma (10X). (c,d) Immunohistochemistry analysis in thyroid lesions showing intense expression for thyroglobulin (10X) and no expression for PSA (10X). (e,f) A small pretracheal metastatic node from papillary thyroid carcinoma (4X and 10X respectively). (g,h) The node showed positive expression for thyroglobulin (10X) and negative expression for PSA negative (4X).|
Click here to view
| Discussion|| |
PSMA based simultaneous PET/MRI is a novel imaging technique which has been used in diagnosis of recurrent prostate carcinoma. PSMA uptake has been demonstrated in both non-prostatic neoplastic,,,, and non-neoplastic lesions., PSMA uptake is also seen in both benign and malignant neoplasms of thyroid.,, Although rare, metastatic spread to the thyroid gland from primary PCa has been reported in the past., In this patient, metastases to the thyroid was a distinct possibility in view of widespread metastatic disease not observed in this case. So, in a case of PSMA avid thyroid lesion, it is important to differentiate metastases with primary thyroid neoplasm with biopsy before initiating further treatment.
Pradeep Negi for technical help in study acquisition and preparation of manuscript
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest
| References|| |
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al
. Comparison of PET/CT and PET/MRI hybrid systems using a 68
Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: Initial experience. Eur J Nucl Med Mol Imaging 2014;41:887-97.
Huang YT, Fong W, Thomas P. Rectal Carcinoma on 68
Ga-PSMA PET/CT. Clin Nucl Med 2016;41:e167-8.
Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B. Vikraman KR, 68
Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:795-6.
Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol 2016;60:514-7.
Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al
. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 2014;14:26.
Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using 68
Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging 2016;43:193-4.
Rowe SP, Deville C, Paller C, Cho SY, Fisherman EK. Pomper MG, et al
. Uptake of 18F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. Tomography 2015;1:81-4.
Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH. Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis. Clin Nucl Med 2015;40:897-8.
Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular Thyroid Adenoma Showing Avid Uptake on 68
Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016;41:331-2.
Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]
PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging 2015;42:1622-3.
Sager S, Vatankulu B, Uslu L, Sonmezoglu K. Incidental Detection of Follicular Thyroid Carcinoma in Ga-68 PSMA PET/CT Imaging. J Nucl Med Technol 2016;44:199-200.
Taywade SK, Damle NA, Bal C. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?. Clin Nucl Med 2016;41:e263-5.
Selimoglu H, Duran C, Saraydaroglu O, Guclu M, Kiyici S, Ersoy C, et al
. Prostate cancer metastasis to thyroid gland. Tumori 2007;93:292-5.
Albsoul NM, Obeidat FN, Hadidy AM, Alzoubi MN, Taib AA, Shahait AD. Isolated multiple bilateral thyroid metastases from prostatic adenocarcinoma: Case report and literature review. Endocr Pathol 2013;24:36-9.
[Figure 1], [Figure 2], [Figure 3]
|This article has been cited by|
||Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center
| ||Marceline W. Piek, Lisa H. de Vries, Maarten L. Donswijk, Bart de Keizer, Jan Paul de Boer, Lutske Lodewijk, Rachel S. van Leeuwaarde, Menno R. Vriens, Koen J. Hartemink, Iris M. C. van der Ploeg |
| ||European Journal of Nuclear Medicine and Molecular Imaging. 2022; |
|[Pubmed] | [DOI]|
||Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT
| ||Kun Tang, Zhiqiang Wang, Jie Lin, Xiangwu Zheng |
| ||Clinical Nuclear Medicine. 2020; 45(3): 223 |
|[Pubmed] | [DOI]|
||Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging
| ||Apurva Sood, Shelvin Kumar Vadi, Rajender Kumar, Harmandeep Singh, Bhagwant Rai Mittal |
| ||Clinical Nuclear Medicine. 2020; 45(4): e217 |
|[Pubmed] | [DOI]|